Bausch + Lomb Swaps CEOs Overnight, and Investors Blink

Your daily brief on leadership and business

Some leadership transitions are planned for years. Others arrive on a Monday. Bausch + Lomb said on October 12, 2026, that chief executive Brent Saunders would leave the eye health company by mutual agreement with its board. No reason was given. Chairman Thomas Appio became interim CEO with immediate effect, and the company's US-listed shares fell more than 7%.

Two companies, one very busy executive

Appio is not new to the building. He also stays on as chief executive of Bausch Health, which owns about 87% of Bausch + Lomb. That makes the interim arrangement unusually compact: the controlling shareholder's CEO now runs the subsidiary as well. Citi described the timing as sudden but said Appio's earlier leadership roles leave him well placed for the job. Leerink was more cautious, warning that an abrupt change could weigh on the stock, especially while investors watch what Bausch Health plans to do with its stake, though it still saw the company on strong fundamental footing.

Saunders' exit closes his second tour at the company. He led Bausch + Lomb from 2010 to 2013, returned in 2023, and in between ran Allergan until its $63 billion sale to AbbVie in 2020. Bausch Health spun off Bausch + Lomb as a public company in 2022 but kept control, and a possible sale process ended without a deal in 2025.

Better numbers, worse timing

The odd part is that the business news was not bad. Based on preliminary third-quarter results, both Bausch + Lomb and Bausch Health expect to raise their 2026 adjusted EBITDA forecasts, excluding acquired research costs. Bausch + Lomb's existing full-year range stood at $1.025 billion to $1.075 billion. Usually a CEO leaves after the numbers disappoint; here the forecast is going up while the chief executive is going out, a combination that leaves investors reading between the lines.